Media coverage about TearLab Corporation (NASDAQ:TEAR) has been trending somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TearLab Corporation earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 83 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- TearLab Corporation (NASDAQ:TEAR) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Elements of Successful Implementation of Dry Eye Diagnostics (eyetube.net)
- Reviewing TearLab Corporation (topix.com)
- TearLab Corporation (TEAR) Expected to Announce Quarterly Sales of $6.72 Million (americanbankingnews.com)
- TearLab Corporation (TEAR) versus LightPath Technologies (LPTH) Critical Contrast (lightwaveonline.com)
A number of equities research analysts have issued reports on TEAR shares. Zacks Investment Research upgraded shares of TearLab Corporation from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Thursday, May 11th. Rodman & Renshaw cut their target price on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of TearLab Corporation in a research report on Tuesday, May 16th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $5.05.
TearLab Corporation (NASDAQ:TEAR) opened at 1.70 on Tuesday. The stock’s 50 day moving average is $1.90 and its 200-day moving average is $3.62. The company’s market cap is $9.75 million. TearLab Corporation has a 12-month low of $1.55 and a 12-month high of $9.00.
TearLab Corporation (NASDAQ:TEAR) last announced its earnings results on Monday, May 15th. The medical research company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to analyst estimates of $7.02 million. During the same period last year, the firm earned ($0.21) EPS. The company’s revenue was down 1.5% compared to the same quarter last year. Analysts predict that TearLab Corporation will post ($2.82) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “TearLab Corporation (TEAR) Earns Daily News Impact Rating of 0.11” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/07/18/somewhat-positive-news-coverage-very-likely-to-affect-tearlab-corporation-tear-stock-price-updated-updated.html.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.